- In April 2024, Takeda Pharmaceutical Company Limited announced the continued global rollout of its dengue vaccine, QDENGA, after receiving additional approvals in Latin American countries including Brazil and Colombia. The vaccine, designed to offer protection against all four dengue virus serotypes regardless of prior exposure, marks a major step forward in preventive care. This development underscores Takeda’s ongoing efforts to expand access to dengue prevention tools in high-burden regions and highlights growing regulatory acceptance of next-generation vaccines
- In March 2024, the World Health Organization (WHO) issued updated dengue treatment and management guidelines, emphasizing early detection, fluid management, and community engagement. These guidelines are aimed at reducing the incidence of severe dengue cases and improving outcomes in low-resource settings. The revision reflects the WHO’s commitment to strengthening global health responses and improving treatment protocols in countries most affected by dengue
- In February 2024, Abbott Laboratories introduced an upgraded version of its Panbio Dengue Rapid Diagnostic Test, which offers improved sensitivity and broader compatibility with field settings. This launch addresses the critical need for quick, accurate dengue detection, especially in rural or underserved regions. The innovation reflects the growing emphasis on decentralized testing and real-time outbreak response in dengue-endemic countries
- In January 2024, Sanofi and the Pasteur Institute initiated a new phase II clinical trial for a monoclonal antibody therapy targeting dengue virus serotype 2. This therapeutic candidate is designed to neutralize the virus and reduce disease severity, offering hope for more targeted treatments beyond symptom relief. The trial represents an important step in diversifying the treatment pipeline and underscores the shift toward biologics in managing vector-borne diseases
- In December 2023, India’s Ministry of Health and Family Welfare launched a nationwide “Dengue Free India” campaign focused on strengthening vector control, improving public awareness, and expanding hospital preparedness. The campaign includes distribution of diagnostic kits, availability of antipyretics at government clinics, and training of healthcare workers. This initiative illustrates the growing role of national health programs in combating dengue and highlights government commitment to reducing the disease burden through multi-faceted intervention strategies
